Evidence map›Paper›PMID 33596675›Full record

Trial reportStroke2021

Quality of Life in Physical, Social, and Cognitive Domains Improves With Endovascular Therapy in the DEFUSE 3 Trial.

Laura C Polding, William J Tate, Michael Mlynash, Michael P Marks, Jeremy J Heit, Soren Christensen, Stephanie Kemp, Gregory W Albers, Maarten G Lansberg, DEFUSE 3 Investigators

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stroke, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02586415 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02586415 naterminatednot on this map

Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3

TypeinterventionalSponsorGregory W AlbersRan2016 to 2017Enrolled182ConditionsStroke, Acute, Cerebral InfarctionArmsEndovascular Thrombectomy, Trevo Retriever, Solitaire™ FR Revascularization Device, Penumbra thrombectomy system, Covidien MindFrame Capture Revascularization Device
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Laura C PoldingStanford University School of Medicine, CA (L.C.P., W.J.T.).
William J TateStanford University School of Medicine, CA (L.C.P., W.J.T.).
Michael MlynashStanford Stroke Center, Palo Alto, CA (M.M., S.C., S.K., G.W.A., M.G.L.).
Michael P MarksDepartment of Radiology, Stanford University School of Medicine, Palo Alto, CA (M.P.M., J.J.H.).
Jeremy J HeitDepartment of Radiology, Stanford University School of Medicine, Palo Alto, CA (M.P.M., J.J.H.).
Soren ChristensenStanford Stroke Center, Palo Alto, CA (M.M., S.C., S.K., G.W.A., M.G.L.).
Stephanie Kemp
Gregory W AlbersStanford Stroke Center, Palo Alto, CA (M.M., S.C., S.K., G.W.A., M.G.L.).
Maarten G LansbergStanford Stroke Center, Palo Alto, CA (M.M., S.C., S.K., G.W.A., M.G.L.).
DEFUSE 3 Investigators
Stanford Medicine · USStanford University · US

Funding

DEFUSE 3: EnDovascular ThErapy Following Imaging EvalUation for ISchemic StrokE 3U01NS092076 · NINDS · STANFORD UNIVERSITY · PI ALBERS, GREGORY W · 2015 to 2016
$5.3M
Stanford University Regional Coordinating Stroke Center for the NIH Stroke Trials NetworkU24NS107220 · NINDS · STANFORD UNIVERSITY · PI MAARTEN G LANSBERG · 2018 to 2026
$2.8M
Stanford University Regional Coordinating Stroke Center for the NINDS Stroke TriaU10NS086487 · NINDS · STANFORD UNIVERSITY · PI ALBERS, GREGORY W · 2013 to 2017
$1.9M
NINDS NIH HHS U01 NS092076NINDS NIH HHS U10 NS086487NINDS NIH HHS U24 NS107220
6 · The paper itself

Abstract

background and purposeThe DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3) randomized clinical trial demonstrated the efficacy of endovascular therapy in treating ischemic stroke 6 to 16 hours after onset, resulting in better functional outcomes than standard medical therapy alone. The objective of this secondary analysis is to analyze the effect of late-window endovascular treatment of ischemic stroke on quality of life (QoL) outcomes.

methodsPatients (n=182) who presented between 6 and 16 hours after they were last known to be well with acute anterior circulation ischemic stroke were randomized to endovascular thrombectomy plus standard medical therapy or standard medical therapy alone and followed-up through 90 days poststroke. QoL at day 90 was assessed with the QoL in Neurological Disorders measurement tool.

resultsOf the 146 subjects alive at day 90, 136 (95%) filled out QoL in Neurological Disorders short forms. Patients treated with endovascular therapy had better QoL scores in each domain: mobility, social participation, cognitive function, and depression (

conclusionsPatients treated with endovascular therapy 6 to 16 hours after stroke have better QoL than patients treated with medical therapy alone, including better mobility, more social participation, superior cognition, and less depression. The modified Rankin Scale fails to capture patients' outcomes in cognition and depression, which should therefore be assessed with dedicated QoL tools. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02586415.

Indexed as

Quality of LifeRecovery of FunctionAgedCognitionEndovascular ProceduresFemaleHumansIschemic StrokeMaleMiddle AgedThrombectomyTime-to-Treatmentcognitive dysfunctiondepressionendovascular proceduresischemic strokequality of life

Identifiers

PMID33596675
PMCPMC7987886
OpenAlexW3130062684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.